PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...

Once a drug target is identified, it often takes decades until a chemical compound is developed that can hit the bullseye and ...

Ultraviolet light causes damage to DNA, leads to cancer and photoaging: age spots and wrinkles. I was curious about this ...

Learn how moving beyond ELISA can streamline your cell line development and boost productivity without compromising results.

A new technical paper titled “The van der Waals Gap: a Hidden Showstopper in Semiconductor Device Scaling” was published by ...

This dual cross-linking design lets the muscle switch stiffness on demand. In lab tests, its stiffness jumps from about 213 ...

PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, Inc., an ...

Scientists at the University of Birmingham have developed a new class of MRI contrast agents, improving their stability to ...

DelveInsight's Chronic Progressive Multiple Sclerosis Market Insights report includes a comprehensive understanding of current treatment practices, chronic progressive multiple sclerosis emerging ...

A $265 million general obligation bond that would allow Des Moines Public Schools to make sweeping changes to the school district is now in the hands of the voters. After a months-long signature drive ...